PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study

被引：1

作者：

Pascual, T. ^{[1
]}

Bermejo De Las Heras, B. ^{[2
]}

Martinez, N. ^{[3
]}

Oliveira, M. ^{[4
]}

Pernas Simon, S. ^{[5
]}

Lopez Lopez, R. ^{[6
]}

Ruiz Cabrero, I. ^{[7
]}

Alarcon, J. D. ^{[8
]}

Martinez De Duenas, E. ^{[9
]}

Malon Gimenez, D. ^{[10
]}

Gonzalez Cao, M. ^{[11
]}

Manso Sanchez, L. M. ^{[12
]}

Morales Murillo, S. ^{[13
]}

Lopez de Ceballos, H. ^{[14
]}

Cortes, J. ^{[15
]}

Llombart Cussac, A. ^{[16
]}

Prat, A. ^{[17
]}

机构：

[1] Hosp Clin Barcelona, Dept Clin Res, SOLTI Canc Res Grp, Barcelona, Spain

[2] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain

[3] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain

[4] Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[5] ICO Inst Catala Oncol Hosp Hosp Duran, Med Oncol Breast Unit, Lhospitalet De Llobregat, Spain

[6] CHUS Complejo Hosp Univ Santiago Composte, Dept Med Oncol, La Coruna, Spain

[7] Hosp Santa Tecla, Dept Med Oncol, Tarragona, Spain

[8] Hosp Univ Son Espases, Dept Med Oncol, Palma De Mallorca, Spain

[9] Hosp Prov Castellon, Med Oncol, Castellon De La Plana, Spain

[10] Hosp Univ Fuenlabrada, Dept Med Oncol, Fuenlabrada, Spain

[11] Hosp Univ Dexeus, Med Oncol, Barcelona, Spain

[12] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[13] Hosp Arnau Vilanova Lleida, Dept Med Oncol, Alpicat, Spain

[14] Hosp San Pedro Alcantara, Med Oncol, Caceres, Spain

[15] VHIO Valle Hebron Inst Oncol, Dept Oncol, Barcelona, Spain

[16] Hosp Arnau Vilanova, Dept Med Oncol, Valencia, Spain

[17] Hosp Clin Prov & Barcelona, Dept Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.03.111

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

95P

引用

页码：S168 / S168

页数：1

共 50 条

[21] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Lu Liu
Mingzhi Zhu
Yanyan Wang
Muhan Li
Yuanting Gu
World Journal of Surgical Oncology, 21
[22] Pathologic Complete Response to Neoadjuvant Chemotherapy Plus Trastuzumab Predicts for Improved Survival in Women With HER2-positive Breast Cancer
Kim, M. M.
Allen, P.
Gonzalez-Angulo, A.
Woodward, W. A.
Meric-Bernstam, F.
Buzdar, A. U.
Hunt, K. K.
Hortobagyi, G. N.
Buchholz, T. A.
Mittendorf, E. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S229 - S229
[23] Neoadjuvant trastuzumab in HER2-positive breast cancer, is pathological complete response enough?
Ruvalcaba-Limon, Eva
Pozo-Romero, Mariela
Bautista-Pina, Veronica
Tenorio-Torres, Alberto
Morales-Vazquez, Flavia
Rodriguez-Cuevas, Sergio
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 342 - 344
[24] Pertuzumab plus trastuzumab increases survival in patients with HER2-positive breast cancer
Mayor, Susan
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (11) : 611 - 611
[25] Complete response after "neoadjuvant" pertuzumab plus trastuzumab plus docetaxel chemotherapy in Her2-positive breast cancer
Lai-Tiong, F.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 836 - 837
[26] Different pCR rates according PAM50 defined subtypes in HER2 positive early breast cancer treated with neoadjuvant pertuzumab and trastuzumab
Diaz-Redondo, T.
Lavado-Valenzuela, R.
Ribelles, N.
Pascual, T.
Galvez, F.
Falcon, A.
Alamo, M. C.
Morales, C.
Amerigo, M.
Prat, A.
Alba, E.
CANCER RESEARCH, 2019, 79 (04)
[27] Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Prat, Aleix
Bianchini, Giampaolo
Thomas, Marlene
Belousov, Anton
Cheang, Maggie C. U.
Koehler, Astrid
Gomez, Patricia
Semiglazov, Vladimir
Eiermann, Wolfgang
Tjulandin, Sergei
Byakhow, Mikhail
Bermejo, Begona
Zambetti, Milvia
Vazquez, Federico
Gianni, Luca
Baselga, Jose
CLINICAL CANCER RESEARCH, 2014, 20 (02) : 511 - 521
[28] The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO
Di Cosimo, S.
Campbell, C.
Azim, H. A., Jr.
Galli, G.
Bregni, G.
Curigliano, G.
Criscitiello, C.
Izquierdo, M.
de la Pena, L.
Fumagalli, D.
Fein, L.
Vinholes, J.
Ng, W. M. J.
Colleoni, M.
Ferro, A.
Naume, B. J.
Patel, A.
Huober, J.
Piccart-Gebhart, M. J.
Baselga, J.
de Azambuja, E.
EUROPEAN JOURNAL OF CANCER, 2018, 89 : 42 - 48
[29] A Multicentre Study of Pathological Complete Response in HER2-positive Early Breast Cancer Treated with Neoadjuvant Pertuzumab and Trastuzumab
Chambers, J.
Maxwell, A.
Kingdon, S.
CLINICAL ONCOLOGY, 2019, 31 (07) : E106 - E106
[30] Neoadjuvant pyrotinib plus trastuzumab, and chemoterapy in patients with HER2-positive early breast cancer: a real-world study
Zhou, Jun
Wang, Rui
CANCER RESEARCH, 2024, 84 (09)

← 1 2 3 4 5 →